

Elena Elez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4623431/publications.pdf>

Version: 2024-02-01

108
papers

9,113
citations

81900

39
h-index

43889

91
g-index

131
all docs

131
docs citations

131
times ranked

12361
citing authors

#	ARTICLE	IF	CITATIONS
1	The Evolving Treatment Landscape in <i>BRAF-V600E</i> Mutated Metastatic Colorectal Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 254-263.	3.8	13
2	Molecular characterization and subsequent treatments after encorafenib-cetuximab +/- binimetinib in BRAF V600E-mutated colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 3562-3562.	1.6	0
3	Impact of circulating tumor DNA (ctDNA) mutant allele fraction in response to anti-angiogenic therapy in <i>RAS</i> -mutant metastatic colorectal cancer (mCRC): Clinical data in the first-line setting and correlation in patient-derived xenograft (PDX) models.. Journal of Clinical Oncology, 2022, 40, 3560-3560.	1.6	0
4	Controversies in the treatment of RAS wild-type metastatic colorectal cancer. Clinical and Translational Oncology, 2021, 23, 827-839.	2.4	3
5	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for <i>RAS</i> Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. Clinical Cancer Research, 2021, 27, 2515-2522.	7.0	39
6	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. Journal of Clinical Oncology, 2021, 39, 273-284.	1.6	254
7	Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. Clinical and Translational Oncology, 2021, 23, 1520-1528.	2.4	4
8	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology, 2021, 299, 109-119.	7.3	54
9	<i>EGFR</i> Amplification in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2021, 113, 1561-1569.	6.3	12
10	Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM). ESMO Open, 2021, 6, 100048.	4.5	7
11	Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 665-677.	10.7	110
12	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 779-789.	10.7	234
13	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).. Journal of Clinical Oncology, 2021, 39, 3505-3505.	1.6	16
14	Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM). ESMO Open, 2021, 6, 100215.	4.5	12
15	Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. European Journal of Cancer, 2021, 155, 168-178.	2.8	1
16	<i>BRAF, MEK</i> and <i>EGFR</i> inhibition as treatment strategies in <i>BRAF</i> V600E metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199297.	3.2	38
17	Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer. Cancers, 2021, 13, 6311.	3.7	30
18	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. European Journal of Cancer, 2020, 138, 1-10.	2.8	23

#	ARTICLE	IF	CITATIONS
19	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K</i>-mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5102-5112.	7.0	23
20	Pembrolizumab in Microsatellite-Instabilityâ€“High Advanced Colorectal Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2207-2218.	27.0	1,513
21	Clinical development of therapies targeting TGFÎ²: current knowledge and future perspectives. <i>Annals of Oncology</i> , 2020, 31, 1336-1349.	1.2	157
22	Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. <i>Lancet Oncology</i> , The, 2020, 21, 1234-1243.	10.7	297
23	Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. <i>JCO Precision Oncology</i> , 2020, 4, 505-513.	3.0	10
24	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 653-664.	3.1	7
25	Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. <i>Clinical Colorectal Cancer</i> , 2020, 19, 165-177.	2.3	15
26	Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. <i>Annals of Oncology</i> , 2020, 31, 1366-1375.	1.2	80
27	Pembrolizumab for the treatment of programmed deathâ€“ligand 1â€“positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTEâ€“028 study. <i>Cancer</i> , 2020, 126, 3021-3030.	4.1	97
28	Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3640-3640.	1.6	8
29	A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4000-4000.	1.6	48
30	Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4032-4032.	1.6	10
31	The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4124-TPS4124.	1.6	14
32	Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA4-LBA4.	1.6	150
33	Patient and tumor characteristics as determinants of overall survival (OS) in BRAF</i> V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4112-4112.	1.6	6
34	The predictive role of plasma mutant allele fraction to antiangiogenic drugs in patients with mCRC: An expanded analysis of surrogate biomarkers of response to first-line treatment with bevacizumab.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3541-3541.	1.6	0
35	Identifying burnout in young oncologists: The sooner the better.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11010-11010.	1.6	0
36	The Medical Oncology resident mentor: situation and workload. <i>Clinical and Translational Oncology</i> , 2019, 21, 304-313.	2.4	4

#	ARTICLE	IF	CITATIONS
37	Impact of circulating tumor DNA mutant allele fraction on prognosis in KRAS mutant metastatic colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 1827-1835.	4.6	40
38	A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2019, 121, 378-383.	6.4	2
39	Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 13568.	3.3	14
40	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1632-1643.	27.0	918
41	Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. <i>Annals of Oncology</i> , 2019, 30, 439-446.	1.2	18
42	Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. <i>Scientific Reports</i> , 2019, 9, 8976.	3.3	34
43	Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. <i>Annals of Oncology</i> , 2019, 30, 796-803.	1.2	21
44	Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 463-471.	4.1	7
45	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1460-1469.	1.6	188
46	Combination of KIR2DS4 and FcγRIIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 2589.	3.3	9
47	First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 674-683.	2.6	16
48	Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis. <i>Cancer Biology and Therapy</i> , 2019, 20, 237-239.	3.4	6
49	Cytokine release syndrome. Reviewing a new entity in the intensive care unit. <i>Medicina Intensiva</i> , 2019, 43, 480-488.	0.7	16
50	Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 688-688.	1.6	14
51	Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1083-1088.	1.3	145
52	Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime?. <i>Annals of Oncology</i> , 2018, 29, 532-534.	1.2	5
53	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1 Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 26-27.	0.4	7
54	Vemurafenib for BRAF V600E Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis. <i>JAMA Oncology</i> , 2018, 4, 384.	7.1	280

#	ARTICLE	IF	CITATIONS
55	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. <i>Clinical Cancer Research</i> , 2018, 24, 794-806.	7.0	177
56	Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1464-1470.	6.4	62
57	The safety of ramucirumab for the treatment of colorectal cancer. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 945-951.	2.4	14
58	PK/PD properties of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking nanobody, in patients (pts) with advanced/metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2523-2523.	1.6	1
59	Impact of cholangiocarcinoma (CC) molecular heterogeneity on outcome during first-line chemotherapy and access to targeted therapies in early clinical trials (CT).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4091-4091.	1.6	1
60	A phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24013-e24013.	1.6	4
61	Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights. <i>Molecular Oncology</i> , 2017, 11, 1263-1272.	4.6	26
62	A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. <i>Cancer Discovery</i> , 2017, 7, 610-619.	9.4	194
63	Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2017, 28, 1294-1301.	1.2	150
64	BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. <i>Annals of Oncology</i> , 2017, 28, 2648-2657.	1.2	227
65	Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer. <i>Science</i> , 2017, 358, 1443-1448.	12.6	983
66	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2535-2541.	1.6	383
67	Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3071-3071.	1.6	107
68	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. <i>PLoS ONE</i> , 2017, 12, e0189848.	2.5	190
69	Unveiling changes in the landscape of patient populations in cancer early drug development. <i>Oncotarget</i> , 2017, 8, 14158-14172.	1.8	8
70	Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1106-1112.	4.1	15
71	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2258-2264.	1.6	52
72	Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 267-282.	2.4	7

#	ARTICLE	IF	CITATIONS
73	Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer. <i>Gastroenterology</i> , 2016, 151, 961-972.	1.3	41
74	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. <i>BMC Cancer</i> , 2016, 16, 339.	2.6	15
75	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in <i>BRAF</i> -Mutant Colorectal Cancer. <i>Cancer Research</i> , 2016, 76, 4504-4515.	0.9	91
76	Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 372-380.	6.4	27
77	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2016, 128, 480-480.	1.4	5
78	Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. <i>Nature Medicine</i> , 2015, 21, 741-750.	30.7	107
79	Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 535-541.	1.2	60
80	First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405. <i>Current Treatment Options in Oncology</i> , 2015, 16, 52.	3.0	66
81	Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. <i>Annals of Oncology</i> , 2015, 26, 132-140.	1.2	87
82	Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d'Hebron Institute of Oncology phase I program cohort.. <i>Journal of Clinical Oncology</i> , 2015, 33, 587-587.	1.6	0
83	Early drug development in advanced gynecologic cancer based on genetic tumor profiling.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5562-5562.	1.6	0
84	A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 2192-2204.	7.0	147
85	Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type <i>KRAS</i> Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4240-4250.	7.0	102
86	Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 6346-6356.	7.0	24
87	Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt322.	6.3	76
88	Prognosis and Therapeutic Implications for Emerging Colorectal Cancer Subtypes. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 55-61.	0.5	4
89	Phase I study of the selective BRAF ^{V600} inhibitor encorafenib (LGX818) combined with cetuximab and with or without the $\text{I}\beta$ -specific PI3K inhibitor BYL719 in patients with advanced <i>BRAF</i> -mutant colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3514-3514.	1.6	19
90	The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study. <i>Blood</i> , 2014, 124, 635-635.	1.4	2

#	ARTICLE	IF	CITATIONS
91	Panitumumab: a summary of clinical development in colorectal cancer and future directions. <i>Future Oncology</i> , 2012, 8, 373-389.	2.4	16
92	Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 4764-4774.	7.0	132
93	Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2062-2071.	4.1	77
94	Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2583-2583.	1.6	3
95	Phase I study of EMD 525797 (DI17E6), an antibody targeting $\alpha_5\beta_1$ integrins, in combination with cetuximab and irinotecan, as a second-line treatment for patients with <i>k-ras</i> wild-type metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3539-3539.	1.6	1
96	Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase. <i>Cancer Research</i> , 2011, 71, 675-685.	0.9	43
97	Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2844-2852.	4.1	81
98	Aprataxin Tumor Levels Predict Response of Colorectal Cancer Patients to Irinotecan-based Treatment. <i>Clinical Cancer Research</i> , 2010, 16, 2375-2382.	7.0	35
99	Panitumumab – an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status. <i>Cancer Treatment Reviews</i> , 2010, 36, S15-S16.	7.7	6
100	New trends in epidermal growth factor receptor-directed monoclonal antibodies. <i>Immunotherapy</i> , 2009, 1, 965-982.	2.0	10
101	The role of salvage treatment in advanced colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 53-61.	4.4	13
102	Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. <i>Cancer Treatment Reviews</i> , 2009, 35, 354-363.	7.7	120
103	Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers. <i>Current Opinion in Oncology</i> , 2009, 21, 374-380.	2.4	3
104	Advances in targeted therapies for metastatic colorectal cancer. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 321-333.	0.2	2
105	Update on Novel Strategies to Optimize Cetuximab Therapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 300-308.	2.3	7
106	Understanding the Predictive Role of K-ras for Epidermal Growth Factor Receptor-Targeted Therapies in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, S52-S57.	2.3	14
107	Oxaliplatin-based chemotherapy in the management of colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1223-1236.	2.4	34
108	Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours. <i>Annals of Oncology</i> , 2008, 19, vii146-vii152.	1.2	10